Actively Recruiting
Precision Radiotherapy for Tumors Using Magnetic Resonance-guided Linear Accelerator (MR-Linac) Observational Study at The Second Affiliated Hospital of Hainan Medical University
Led by The Second Affiliated Hospital of Hainan Medical University · Updated on 2025-02-13
3000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of MR-Linac, a magnetic resonance-guided linear accelerator, for precise radiotherapy treatment of tumors. This observational study aims to assess how well this technology works in reducing tumor size, its side effects, and detailed dosimetric characteristics. The study is sponsored by The Second Affiliated Hospital of Hainan Medical University and focuses on oncology patients aged 18 to 75 years with a good performance status. The treatment involves radiation therapy using the MR-Linac device, which allows for precise targeting of tumors during radiotherapy. Patients included are those currently receiving or who have received imaging or treatment with the MR-Linac. The study tracks various outcomes over time, including tumor response, survival rates, disease control, adverse reactions, quality of life, and specific radiation dose parameters measured during treatment. Participants will undergo regular assessments at multiple time points ranging from 3 months up to 60 months after treatment. These assessments include tumor imaging to measure response rates, survival monitoring, evaluation of side effects using standard toxicity criteria, quality of life questionnaires, and analysis of radiation dose delivered to targeted areas and organs at risk. The study seeks to gather comprehensive data on the effectiveness and safety of MR-Linac guided radiotherapy in tumor management over several years.
CONDITIONS
Brief Title
Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients are undergoing or have undergone imaging or treatment at the MR Linac
- Age between 18 and 75 years, male or female
- ECOG score of 0 to 2
- Life expectancy greater than 6 months
- Patients provide written informed consent
You will not qualify if you...
- Contraindications to MRI such as claustrophobia or incompatible metallic or electronic implants
- Severe comorbidities that prevent tolerating or completing radiotherapy
- Acute inflammatory disease requiring systemic therapy
- Presence of active infectious disease
- Pregnant women, nursing mothers, or patients planning to have children during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During Radiotherapy
Participants undergo precision radiotherapy using the MR-Linac device with dosimetric parameters monitored during treatment.
Multiple visits during radiotherapy treatment
Duration - Up to 60 months
Participants are monitored for tumor response, progression-free survival, disease control, overall survival, adverse reactions, and quality of life for up to 60 months after treatment.
Visits at 3, 6, 12, 24, 36, and 60 months post-treatment
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Hainan Medical University
Haikou, China, 570311
Actively Recruiting
Research Team
J
junnv xu, doctor
Y
yuecan zeng, doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here